The need addressed
Access to breast screening
What we know
NIRAMAI describes a portable screening approach with referrals for further diagnostic imaging when indicated. This description is not an independent assessment or a recommendation to replace established screening.
Access & commercial model
These fields describe this offering only. Geography refers to access, not headquarters. Customer, payer and user can differ.
- Markets served
- Not established — not yet researched.Not yet researched
- Customer / contracting party
- Hospitals, diagnostic centres and programme organisers described as use settingsSource documented · Source · 29 September 2026
- Who pays
- Not established — not yet researched.Not yet researched
- Route to market
- Provider screening, public-health programmes and corporate wellness described by companySource documented · Source · 29 September 2026
- Access & availability
- Not established — not yet researched.Not yet researched
- Sales evidence
- Offering-specific sales or revenue not found in the reviewed page.Not found in reviewed source · Source · 29 September 2026This is a statement about this source, not all public disclosures. Company-wide reach and clinical outcomes are different measures.
Connected records
Provided by · OrganisationNIRAMAI →Study of this technology · ResearchThermalytix observational study →Source & scope
NIRAMAI Thermalytix overview ↗
Company technology description. Review date: 29 September 2026. A source link documents the stated relationship; it does not imply independent validation of outcomes.
Health-need and context tags are editorial classifications. Availability can change. Read the methodology.